CompletedPhase 2NCT00739388
Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swiss Cancer Institute
- Principal Investigator
- Jakob Passweg, ProfHopitaux Universitaires de Geneve
- Intervention
- azacytidine(drug)
- Enrollment
- 47 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2012
Study locations (11)
- Kantonspital Aarau, Aarau, Switzerland
- Kantonsspital Baden, Baden, Switzerland
- Universitaetsspital-Basel, Basel, Switzerland
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- Inselspital Bern, Bern, Switzerland
- Spitalzentrum Biel, Biel, Switzerland
- Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- Kantonsspital, Luzerne, Luzerne, Switzerland
- Kantonsspital - St. Gallen, Sankt Gallen, Switzerland
- Hopitaux Universitaires de Geneve, Thonex-Geneve, Switzerland
- UniversitaetsSpital Zuerich, Zurich, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00739388 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.